Table 4 COVID-19 pharmacological therapies and association with mortality in patients with hematologic malignancies and COVID-19, according to clinical severity of COVID-19: time-to-event analysis
N (%), patients | n, events | Clinical severity of COVID-19 | ||||||
|---|---|---|---|---|---|---|---|---|
Mild/moderate | Severe/critical | |||||||
Patients with data on clinical severity of COVID-19 | 692 (100) | 227 | 263 patients; 15 events | 429 patients; 212 events | ||||
Analysis of association with mortality | Univariable | Multivariable* | Univariable | Multivariable† | ||||
HR‡ (95% CI) | P value | HR‡ (95% CI) | P value | |||||
COVID-19 pharmacological therapy | ||||||||
Antiviral therapy | ||||||||
Hydroxychloroquine | 558 (81) | 184 | 0.92 (0.29–2.92) | 1.22 (0.33–4.56) | 0.8 | 0.40 (0.28–0.57) | 0.38 (0.27–0.56) | < 0.001 |
Azithromycin | 276 (40) | 90 | 1.25 (0.44–3.52) | 1.57 (0.54–4.56) | 0.6 | 0.69 (0.52–0.90) | 0.67 (0.58–0.89) | 0.006 |
Antiretrovirals | 337 (49) | 116 | 1.16 (0.42–3.22) | 1.70 (0.57–5.04) | 0.4 | 0.77 (0.59–1.01) | 0.91 (0.69–1.20) | 0.5 |
β-interferon | 50 (7) | 27 | 1.28 (0.17–9.78) | 2.12 (0.27–16.8) | 0.5 | 1.53 (1.01–2.32) | 1.52 (1.00–2.30) | 0.051 |
Antiviral combination therapy | ||||||||
No therapy | 116 (17) | 33 | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||
Hydroxychloroquine alone | 86 (12) | 34 | 1.11 (0.19–6.69) | 1.19 (0.16–8.60) | 0.8 | 0.72 (0.43–1.20) | 0.54 (0.31–0.92) | 0.024 |
Hydroxychloroquine and azithromycin | 148 (21) | 40 | 0.66 (0.11–3.93) | 0.94 (0.13–6.71) | 0.6 | 0.35 (0.22–0.58) | 0.34 (0.21–0.57) | < 0.001 |
Hydroxychloroquine and antiretrovirals | 208 (30) | 68 | 1.02 (0.23–4.58) | 1.52 (0.27–8.63) | 0.9 | 0.43 (0.28–0.68) | 0.48 (0.30–0.77) | 0.002 |
Hydroxychloroquine, azithromycin and antiretrovirals | 116 (17) | 42 | 1.80 (0.36–8.96) | 4.57 (0.70–29.7) | 0.14 | 0.40 (0.25–0.66) | 0.40 (0.24–0.67) | < 0.001 |
Adjuvant therapy | ||||||||
Systemic corticosteroids | 318 (46) | 133 | 2.43 (0.86–6.82) | 2.34 (0.80–6.76) | 0.13 | 0.88 (0.67–1.16) | 1.01 (0.76–1.35) | 0.9 |
Tocilizumab | 132 (19) | 51 | 5.07 (1.61–15.9) | 5.94 (1.80–19.6) | 0.002 | 0.62 (0.45–0.86) | 0.87 (0.62–1.23) | 0.4 |